US Federal Senate Bill SB1302

US Federal 2025-2026 Regular Session

• Introduced: 4/3/25
• Refer: 4/3/25

Caption

Increasing Transparency in Generic Drug Applications Act

Impact

If enacted, this legislation will have significant implications for the regulatory framework governing generic pharmaceuticals. The bill mandates that the FDA disclose information about any differences in drug formulations to applicants, which could lead to a more transparent assessment process. This is expected to empower manufacturers by providing clarity on the potential for bioequivalence, improving the chances of successful applications. Moreover, it enhances the accountability of the FDA in dealing with generic drug submissions, which may lead to increased trust among stakeholders in the healthcare system.

Summary

Senate Bill 1302, titled the 'Increasing Transparency in Generic Drug Applications Act,' seeks to enhance the transparency of the drug approval process under the Federal Food, Drug, and Cosmetic Act. The bill amends Section 505(j)(3) to require the Secretary of Health and Human Services to inform applicants whether a generic drug is qualitatively and quantitatively the same as its listed counterpart. This aims to facilitate a clearer communication channel between generic drug manufacturers and regulatory bodies, ensuring that doubts about equivalency can be addressed early in the application process.

Contention

During discussions surrounding SB1302, some points of contention emerged, particularly regarding the potential for disclosure of proprietary information. Critics expressed concerns that while transparency is crucial, it could also risk the commercialization of sensitive trade secrets held by brand-name drug manufacturers. Balancing transparency with the protection of intellectual property remains a pivotal debate among legislators and industry representatives as the bill moves forward in the legislative process.

Congress_id

119-S-1302

Introduced_date

2025-04-03